Treatment of lymphangiogenic tumors with inhibitors of VEGF Receptor 3 (VEGFR3) to specifically attenuate proliferation and activation of lymphatic endothelial cells (LECs) inhibits lymph node and systemic metastasis in multiple models of cancer (16, 17). This evidence concerns the gene FLT4 and cancer.